Loading...
Date of Award
Spring 2020
Degree Name
Master of Medical Science (Physician Assistant)
Department
Physician Assistant; College of Health Sciences
First Advisor
Amanda Seymour
Abstract
Chronic kidney disease (CKD) is a progressive disease process
that leads to a decline in kidney function and eventual kidney
failure. One of the leading causes of CKD is type 2 diabetes.
Novel diabetic agents have been developed and have shown
promise in slowing the progression of CKD in patients with type
2 diabetes. The purpose of this review was to compare SGLT-2
inhibitors (I) and GLP-1 receptor agonists (C) to determine their
impact on nephropathy indicators (O) in type 2 diabetic patients
with CKD (P).
Recommended Citation
Kaye, Emily, "Comparison of two novel agents in slowing the progression of chronic kidney disease in patients with type 2 diabetes" (2020). Capstone Showcase. 69.
https://scholarworks.arcadia.edu/showcase/2020/pa/69
Comparison of two novel agents in slowing the progression of chronic kidney disease in patients with type 2 diabetes
Chronic kidney disease (CKD) is a progressive disease process
that leads to a decline in kidney function and eventual kidney
failure. One of the leading causes of CKD is type 2 diabetes.
Novel diabetic agents have been developed and have shown
promise in slowing the progression of CKD in patients with type
2 diabetes. The purpose of this review was to compare SGLT-2
inhibitors (I) and GLP-1 receptor agonists (C) to determine their
impact on nephropathy indicators (O) in type 2 diabetic patients
with CKD (P).